株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

トランスサイレチン:パイプライン製品の分析

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 251567
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
トランスサイレチン:パイプライン製品の分析 Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017
出版日: 2017年10月10日 ページ情報: 英文 74 Pages
概要

当レポートでは、トランスサイレチンの開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

トランスサイレチンの概要

治療薬の開発

トランスサイレチン:開発中の製品 - 開発段階別

トランスサイレチン:開発中の製品 - 治療範囲別

トランスサイレチン:開発中の製品 - 適応症別

トランスサイレチン:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

トランスサイレチン:企業で開発中の製品

トランスサイレチン:大学/機関で開発中の製品

トランスサイレチン:治療薬の評価

  • 単剤療法/併用療法製品別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

トランスサイレチンの治療薬開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc
  • Neurimmune Holding AG
  • Pfizer Inc.
  • Prothena Corporation Plc
  • Regeneron Pharmaceuticals, Inc.
  • SOM Innovation Biotech SL

薬剤プロファイル

休止中のプロジェクト

主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC1052TDB

Summary:

According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome.

The report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017' outlays comprehensive information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2, 2 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Cardiovascular which include indications Familial Amyloid Neuropathies, Amyloidosis, Amyloid Cardiomyopathy, Familial Amyloid Cardiomyopathy, Alzheimer's Disease, Cardiomyopathy and Neuropathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview
    • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals Inc
    • Arcturus Therapeutics Inc
    • Ionis Pharmaceuticals Inc
    • Neurimmune Holding AG
    • Pfizer Inc
    • Prothena Corp Plc
    • Regeneron Pharmaceuticals Inc
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles
    • AG-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-TTRsc02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CRX-1008 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxycycline hyclate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1307 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inotersen sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUNAR-TTR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NI-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patisiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tafamidis meglumine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Products
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products
  • Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 28, 2017: Eidos Therapeutics Initiates First Clinical Study for AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis as Chief Business Officer
      • Sep 20, 2017: Arbutus' LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
      • Sep 20, 2017: Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
      • Aug 31, 2017: Amyloid Publishes Long-term Data Analysis From Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease
      • Jul 18, 2017: Proclara Biosciences Presents New Preclinical Data Supporting the Development of NPT189 at Alzheimer's Association International Conference (AAIC) 2017
      • Jul 17, 2017: Proclara Biosciences Provides Update on NPT189
      • Jul 10, 2017: New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen
      • Jun 06, 2017: Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy
      • May 15, 2017: Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
      • Apr 27, 2017: BridgeBio Pharma Launches Eidos Therapeutics to Develop Targeted Therapy for Fatal Heart Disease
      • Apr 26, 2017: Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
      • Mar 10, 2017: Proclara Biosciences Australia, a Subsidiary of Proclara Biosciences, Awarded Grant by Biopharmaceuticals Australia to Help Develop New Biotherapy with Blockbuster Potential
      • Nov 07, 2016: VYNDAQEL (tafamidis) Receives Approval in Brazil by ANVISA for the Treatment of Transthyretin Familial Amyloid Polyneuropathy
      • Oct 10, 2016: Data Monitoring Committee Recommends Continuation of APOLLO Phase 3 Clinical Trial of Patisiran for Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
      • Aug 08, 2016: Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Pipeline by Arcturus Therapeutics Inc, H2 2017
  • Pipeline by Ionis Pharmaceuticals Inc, H2 2017
  • Pipeline by Neurimmune Holding AG, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Prothena Corp Plc, H2 2017
  • Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top